Comparative Pharmacology
Head-to-head clinical analysis: DIANEAL LOW CALCIUM W DEXTROSE 3 5 IN PLASTIC CONTAINER versus INPERSOL LC LM W DEXTROSE 3 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIANEAL LOW CALCIUM W DEXTROSE 3 5 IN PLASTIC CONTAINER versus INPERSOL LC LM W DEXTROSE 3 5 IN PLASTIC CONTAINER.
DIANEAL LOW CALCIUM W/DEXTROSE 3.5% IN PLASTIC CONTAINER vs INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DIANEAL LOW CALCIUM W/DEXTROSE 3.5% provides a hyperosmotic solution for peritoneal dialysis. Dextrose generates an osmotic gradient across the peritoneal membrane, promoting fluid and solute removal (ultrafiltration). Low calcium content helps manage hypercalcemia in patients requiring peritoneal dialysis.
Inpersol-LC/LM with 3.5% dextrose is a peritoneal dialysis solution that provides osmotic ultrafiltration via dextrose, removing waste products and excess fluid from the blood across the peritoneal membrane. The low calcium (LC) and low magnesium (LM) formulations adjust electrolyte concentrations to manage imbalances.
Intraperitoneal: 2-3 L per exchange, 4-5 exchanges daily, as prescribed by physician based on body size and residual renal function.
Intraperitoneal administration: 2 to 2.5 liters per exchange, 4 to 5 exchanges per day, as prescribed by physician based on peritoneal equilibration test.
None Documented
None Documented
Not applicable; drug is not systematically absorbed. Dextrose has half-life of ~1.5-2 hours after absorption.
Not applicable; dextrose is continuously infused and removed; the half-life of intraperitoneal dextrose is approximately 1-2 hours due to rapid absorption and metabolism, with clinically relevant hyperglycemia managed by insulin.
Primarily removed via peritoneal dialysis; negligible renal excretion due to local administration. Dextrose is metabolized systemically; dialysate is drained as waste.
Renal (via peritoneal dialysis effluent); approximately 60-70% of administered dextrose is absorbed and metabolized, with the remainder removed in dialysate; no significant biliary/fecal elimination.
Category C
Category C
Peritoneal Dialysis Solution
Peritoneal Dialysis Solution